SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalVIVO: MERIDIAN BIOSCIENCE INC(NASDAQ)


Next 10 
To: Savant who started this subject5/22/2001 10:21:35 AM
From: Savant
   of 14
 
Meridian Bioscience Reports On Profitable Operations, Increased Production and Plans to Expand Credit Facility

CINCINNATI--(BW HealthWire)--May 22, 2001--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced operating results for the month of
April were profitable, consistent with the Company's earlier public
statements that it expected operating results would become profitable
during the current quarter. Quoting from the April 24, 2001, press
release, "Notwithstanding the operating losses reported for the second
quarter and first half of fiscal 2001, meaningful progress has been
made in improving Meridian's quality systems, strengthening the
management team, resuming product shipments, managing customer
relations and moving toward profitable operations." Production for the
month ended April 30, 2001 increased more than twofold over the low
point reached during the second fiscal quarter. The gross profit
margin for April was 63%, primarily as a result of higher production
levels and favorable product mix, up from 50% for the second quarter.
Both the Company's U.S. and European operating divisions operated at a
profit during April.
Meridian also reported that it is in the process of negotiating an
expansion from $22.5 million to $25 million of its commercial bank
credit facility that expires December 2001. At April 30, 2001,
borrowings of $11.1 million were outstanding. The Company's balance
sheet is sound and expected to increase in strength during the second
half of fiscal 2001. At March 31, 2001, current assets were
$35.3 million as compared to current liabilities of $16.7 million,
thereby producing net working capital of $18.6 million and a current
ratio of 2.1 Cash and equivalents were $4.2 million. Long-term debt
obligations were $26.5 million compared to shareholders' equity of
$25.4 million.
As stated previously, barring unforeseen circumstances, Meridian
does not anticipate problems with regard to liquidity or its ability
to meet its working capital needs, capital expenditure plans,
contractual payments or indicated cash dividend requirements. The
Company's indicated annual cash dividend rate is $0.26 per common
share and the most recent quarterly cash dividend of $0.065 per common
share was paid May 9, 2001.
John A. Kraeutler, President and Chief Operating Officer, stated,
"We are very pleased that operations have improved substantially since
February, as planned, and that we achieved profitable operations
during the month of April, even after on-going special charges
relating to FDA compliance and litigation costs." He further stated,
"Our employees are doing a great job of improving the Company's
operations and quality systems. We look forward to reporting
additional progress and more good news in the near future."

FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a
safe harbor from civil litigation for forward-looking statements
accompanied by meaningful cautionary statements. These statements
identify important factors that could cause actual results to differ
materially from those that might be projected. Meridian's continued
growth depends, in part, on its ability to introduce into the
marketplace enhancements of existing products or new products that
incorporate technological advances, meet customer requirements and
respond to products developed by Meridian's competition. While
Meridian has introduced approximately 35 internally-developed products
since 1991, there can be no assurance that it will be successful in
the future in introducing such products on a timely basis. Ongoing

consolidations of reference laboratories and formation of
multi-hospital alliances may cause adverse changes to pricing and
distribution. Costs and difficulties in complying with laws and
regulations administered by the United States Food and Drug
Administration can result in unanticipated expenses and delays and
interruptions to the sale of new and existing products. One of
Meridian's main growth strategies is acquisition of companies and
product lines. There can be no assurance that additional acquisitions
will be consummated or that, if consummated, will be successful and
the acquired businesses successfully integrated into Meridian's
operations.
Meridian is a fully integrated life sciences company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and
offers biopharmaceutical enabling technologies. Utilizing a variety of
methods, these products provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral, urinary and respiratory infections. All
Meridian products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents and specialty biologicals. The Company
markets its products to hospitals, reference laboratories, research
centers, veterinary testing centers and physician offices in more than
60 countries around the world. The Company's shares are traded through
Nasdaq's National Market, symbol VIVO. Meridian's website address is
www.meridianbioscience.com.

--30--slb/clv*

CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513/271-3700

KEYWORD: OHIO
INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY PHARMACEUTICAL MEDICAL
DEVICES

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Savant who wrote (1)4/13/2005 12:37:29 PM
From: hyperal
   of 14
 
This appears to be very bad news for Meridian Bioscience

I quote from The New Scientist quoted from

www.newscientist.com/article.ns?id=dn7261

"The virus that caused the 1957 “Asian flu” pandemic has been accidentally released by a lab in the US, and sent all over the world in test kits which scientists are now scrambling to destroy.

There are fears the virus could escape the labs, as the mistake was discovered after the virus escaped from a kit at a high-containment lab in Canada. Such an escape could spread worldwide, as demonstrated in Russia in the 1970s.

The flu testing kits were sent to some 3700 labs between October 2004 and February 2005 by the College of American Pathologists (CAP), a professional body which helps pathology laboratories improve their accuracy, by sending them unidentified samples of various germs to identify.

The CAP kits - prepared by private contractor Meridian Bioscience in Cincinnati, US - were to contain a particular strain of influenza A - the viral family that causes most flu worldwide. But instead of choosing a strain from the hundreds of recently circulating influenza A viruses, the firm chose the 1957 pandemic strain."

What annoys me is Meridian Bioscience don't even mention it on their website.

If this flu gets into the human population, then whoever was responsible for allowing it to happen will pay a very heavy price! The 1957 flu pandemic killed an estimated two million or more people!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: hyperal who wrote (2)4/13/2005 8:20:54 PM
From: Savant
   of 14
 
No bad news. Just a flurry of press. People that probably haven't ever heard of VIVO before, have now.
It will only get into the 'wild', if the labs that have received it don't follow protocol.

Unlikely that anything adverse monetarily will happen to VIVO, as they didn't do anything out of bounds.

Now, as to whether they, or the folks with the strains, should have had rules or regs in place precluding such an occurrence or choice of strains, yes, they should have had, in my opinion.

Best,
S.

Share RecommendKeepReplyMark as Last Read


From: tnsaf4/19/2006 8:44:41 PM
   of 14
 
Meridian Bioscience Helicobacter Pylori Patent Validated by Settlement Agreement With Astra S.r.l.
Wednesday April 12, 9:22 am ET

CINCINNATI--(BUSINESS WIRE)--April 12, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO - News) today announced that it has executed a settlement agreement with Astra S.r.l. regarding Meridian's patented technology for detecting H. pylori, the primary cause of peptic ulcers. In the agreement, Astra acknowledges the existence, validity and scope of Meridian's patent, EPO 0806667. Astra further agrees to: 1) cease all promotion and distribution of its infringing products, and; 2) for any existing customers, to replace the Astra product with Meridian HpSA products(s).

John A. Kraeutler, President and Chief Operating Officer, stated, "Meridian's investment in technology for detecting H. pylori bacteria has been significant. We are very pleased to have reached agreement with Astra regarding the validity of our patent and we will continue our focus on the development of new diagnostic technologies for emerging infectious disease markets."

Share RecommendKeepReplyMark as Last Read


From: tnsaf9/15/2006 1:20:56 AM
   of 14
 
Meridian makes SmallCap 600
Thursday September 14, 10:39 am ET

Meridian Bioscience Inc. will be listed on the SmallCap 600, Standard & Poor's said Wednesday.

The Cincinnati-based biomedical company will replace MRO Software Inc. (NYSE: MRO - News), which is being acquired by IBM Corp. (NYSE: IBM - News), according to a MarketWatch report.

Meridian (NASDAQ: VIVO - News) will be listed on the SmallCap 600 after the close of trading Sept. 18. Shares of Meridian were trading at $23.94, up $1.52, Thursday morning.

The SmallCap 600 invests in 600 companies with a market capitalization of between $300 million and $2 billion. To be included, a company must also meet financial viability, liquidity and other trading requirements.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tnsaf who wrote (5)9/16/2006 1:09:52 PM
From: Savant
   of 14
 
This co, that used to be KITS, just keeps chugging along.

Best,
S.

Share RecommendKeepReplyMark as Last Read


From: tnsaf11/14/2007 10:22:29 PM
   of 14
 
Meridian Bioscience Profit Up 36 Percent
Wednesday November 14, 12:52 pm ET
Meridian Bioscience Profit Rises 36 Percent Amid Higher Demand for Diagnostic Test Products

CINCINNATI (AP) -- Meridian Bioscience Inc., which makes diagnostic test kits, said Wednesday profit rose 36 percent in its fiscal fourth quarter, as higher demand for diagnostic products drove revenue growth.

For the quarter ended Sept. 30, the company earned $6.4 million, or 16 cents per share, compared with $4.7 million, or 12 cents per share, a year ago.

Revenue rose 13 percent to $32.4 million from $28.7 million, benefiting from double-digit sales increases across all the company's business units.

Analysts polled by Thomson Financial expected profit of 15 cents per share, on revenue of $32.6 million.

Full-year earnings rose 46 percent to $26.7 million, or 66 cents per share, from $18.3 million, or 46 cents per share. Excluding a one-time tax benefit, adjusted earnings for 2007 totaled 60 cents per share.

Revenue for fiscal 2007 gained 13 percent to $123 million from $108.4 million.

For the fourth quarter, "our diagnostics businesses performed very well, led by tests for hospital-acquired infections, respiratory disease, stomach ulcers and food-borne infections," said John A. Kraeutler, president and chief operating officer.

U.S. diagnostics sales rose 10 percent to $19 million from $17.2 million.

In a note to investors, Soleil Securities Group analyst Elliott L. Schlang maintained his estimates on the company and kept his rating at "Hold."

Shares of Meridian fell 65 cents, or 2.1 percent, to $30.20 in midday trading.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tnsaf who wrote (7)11/14/2007 10:24:00 PM
From: tnsaf
   of 14
 
Meridian Bioscience Affirms 2008 Outlook
Wednesday November 14, 2:49 pm ET
Meridian Bioscience Reiterates 2008 Earnings, Revenue Guidance, Citing Diagnostics Units

CINCINNATI (AP) -- Meridian Bioscience Inc., which makes diagnostic test kits, Wednesday reaffirmed its fiscal 2008 earnings and revenue guidance, citing growth in its diagnostics business.

The company expects earnings for fiscal 2008, which ends in September 2008, in the range of 72 cents per share and 75 cents per share.

Meridian forecasts revenue to be between $140 million and $142 million.

Analysts surveyed by Thomson Financial, on average, estimate 2008 earnings of 73 cents per share on revenue of $141.8 million.

"Entering fiscal 2008, we believe the growth drivers within the diagnostics business units continue to be robust. We are delighted with the early success of ImmunoCard STAT! EHEC, a test to rapidly diagnose people infected with the toxin-producing forms of E. coli bacteria," said President and Chief Operating Officer John A. Kraeutler, in a statement.

The company also said it will launch several diagnostic tests during the first quarter, as the life science business is poised to roll out new biologics products during the next 60 to 90 days.

In a note to investors, Soleil Securities Group analyst Elliott L. Schlang maintained his estimates on the company and kept his stock rating at "Hold."

Shares of Meridian Bioscience fell 60 cents to $30.25 in afternoon trading.

Share RecommendKeepReplyMark as Last Read


From: mlkr7/18/2008 2:52:54 PM
   of 14
 
prety quite in here?

Share RecommendKeepReplyMark as Last Read


From: Savant10/5/2016 5:18:46 PM
   of 14
 
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) is proud to announce that the London R&D and Berlin manufacturing facilities are now fully accredited to the ISO 13485 quality standard.

Bioline recognizes the importance of adhering to a quality management system in the development, manufacture and supply of test components to the molecular diagnostic arena. We are committed to strengthening our relationships by meeting the quality standard our industrial partners need in their efforts to achieve test certification. Consequently, Bioline is delighted to announce that our production facilities in Berlin and research facilities in London are now certified to ISO 13485 quality standard. Our full range of industrial services includes custom assay development, bulk supply of test components, validation support, and private label OEM manufacture.

Marco Calzavara, President of Bioline, commented, "Our ISO 13485 certification means we offer complete confidence in Bioline as the supplier of molecular diagnostic test components. Our certification demonstrates our reproducibly high standards of quality, manufacturing consistency, material traceability and complete supply chain security. We look forward to expanding our contribution to the development of molecular diagnostic tests that improve animal and human health. Our own product development efforts are also guided by ISO 13485. We recently expanded our product portfolio to include a lyophilization-ready qPCR reagent, namely the SensiFAST(TM) Lyo-Ready No-ROX Mix, to assist our partners in the development of IVD tests."

Richard L. Eberly, President, Chief Commercial Officer, stated, "Our ISO 13485 certification is an important milestone in the progression of Bioline. Our adherence to this quality standard builds on our understanding of our diagnostic partner's requirements and demonstrates our commitment to being a trusted supplier in the development of new in vitro molecular diagnostic tests into the future. We look forward to strengthening our existing business and forging new relationships with diagnostic manufacturers for their bulk and custom needs within the framework of the ISO 13485 quality management system."

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections and blood lead levels. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections; serology, parasitology and fungal disease diagnosis, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

FOR ADDITIONAL INFORMATION:

For more information about Bioline, please visit bioline.com.

CONTACT: Richard L. Eberly President, Chief Commercial Officer Meridian Bioscience, Inc. Phone: 513.271.3700 Rick.eberly@meridianbioscience.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Next 10